Biomedical research at Oslo University Hospital

Publications (original articles or review articles) published in 2018 from OUS - Section of Preventive Medicine

30 publications found

Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E, Norat T (2018)
Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies
Am J Clin Nutr, 108 (5), 1069-1091
DOI 10.1093/ajcn/nqy097, PubMed 30475962

Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM (2018)
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial
JAMA Intern Med, 178 (5), 622-631
DOI 10.1001/jamainternmed.2018.0397, PubMed 29630702

Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS (2018)
Inflammatory and Cholesterol Risk in the FOURIER Trial
Circulation, 138 (2), 131-140
DOI 10.1161/CIRCULATIONAHA.118.034032, PubMed 29530884

Botteri E, de Lange T, Tonstad S, Berstad P (2018)
Exploring the effect of a lifestyle intervention on cancer risk: 43-year follow-up of the randomized Oslo diet and antismoking study
J Intern Med, 284 (3), 282-291
DOI 10.1111/joim.12765, PubMed 29790221

Cwikiel J, Seljeflot I, Berge E, Njerve IU, Ulsaker H, Arnesen H, Flaa A (2018)
Effect of strenuous exercise on mediators of inflammation in patients with coronary artery disease
Cytokine, 105, 17-22
DOI 10.1016/j.cyto.2018.02.006, PubMed 29433015

Dufour R, Hovingh GK, Guyton JR, Langslet G, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
J Clin Lipidol, 13 (1), 138-147
DOI 10.1016/j.jacl.2018.11.007, PubMed 30591415

Engeseth K, Prestgaard EE, Mariampillai JE, Grundvold I, Liestol K, Kjeldsen SE, Bodegard J, Erikssen JE, Gjesdal K, Skretteberg PT (2018)
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men
Eur J Prev Cardiol, 25 (15), 1655-1663
DOI 10.1177/2047487318793459, PubMed 30103630

Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR (2018)
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Atherosclerosis, 278, 307-314
DOI 10.1016/j.atherosclerosis.2018.08.036, PubMed 30293878

Gaudet D, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A (2018)
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
J Clin Lipidol, 12 (5), 1199-1207
DOI 10.1016/j.jacl.2018.05.007, PubMed 30318065

Holven KB, Narverud I, van Lennep JR, Versmissen J, Øyri LKL, Galema-Boers A, Langslet G, Ulven SM, Veierød MB, Retterstøl K, Bogsrud MP (2018)
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
J Clin Lipidol, 12 (3), 748-755.e2
DOI 10.1016/j.jacl.2018.02.021, PubMed 29609857

Hovingh GK, Guyton JR, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia
J Clin Lipidol, 12 (6), 1463-1470
DOI 10.1016/j.jacl.2018.08.011, PubMed 30287210

Hovland A, Mundal LJ, Igland J, Veierød MB, Holven KB, Bogsrud MP, Tell GS, Leren TP, Retterstøl K (2018)
Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia
Stroke, 50 (1), 172-174
DOI 10.1161/STROKEAHA.118.023456, PubMed 30580708

Jortveit J, Kaldal A, Tonstad S (2018)
Prevalence of diabetes before and after first diagnosis of coronary artery disease
Tidsskr Nor Laegeforen, 138 (5)
DOI 10.4045/tidsskr.17.0539, PubMed 29513466

Korman MJ, Retterstøl K, Kristiansen IS, Wisløff T (2018)
Are PCSK9 Inhibitors Cost Effective?
Pharmacoeconomics, 36 (9), 1031-1041
DOI 10.1007/s40273-018-0671-0, PubMed 29777433

Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceška R, López-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MS (2018)
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial
JAMA Cardiol, 3 (8), 749-753
DOI 10.1001/jamacardio.2018.1533, PubMed 29898218

McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH (2018)
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
Am J Cardiol, 121 (8), 940-948
DOI 10.1016/j.amjcard.2017.12.040, PubMed 29472008

Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, Mancia G, Parati G, Weber MA, Berge E (2018)
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks
Eur Heart J, 39 (24), 2243-2251
DOI 10.1093/eurheartj/ehx760, PubMed 29365085

Mundal LJ, Igland J, Veierød MB, Holven KB, Ose L, Selmer RM, Wisloff T, Kristiansen IS, Tell GS, Leren TP, Retterstøl K (2018)
Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
Heart, 104 (19), 1600-1607
DOI 10.1136/heartjnl-2017-312706, PubMed 29622598

Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE (2018)
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Clin Cardiol, 41 (10), 1281-1288
DOI 10.1002/clc.23055, PubMed 30125052

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Heart Fail Rev, 23 (3), 303-323
DOI 10.1007/s10741-018-9685-0, PubMed 29516230

Retterstøl K, Svendsen M, Narverud I, Holven KB (2018)
Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: A randomized controlled study
Atherosclerosis, 279, 52-61
DOI 10.1016/j.atherosclerosis.2018.10.013, PubMed 30408717

Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR (2018)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Circulation, 138 (8), 756-766
DOI 10.1161/CIRCULATIONAHA.118.034309, PubMed 29626068

Svendsen K, Henriksen HB, Østengen B, Jacobs DR, Telle-Hansen VH, Carlsen MH, Retterstøl K (2018)
Evaluation of a short Food Frequency Questionnaire to assess cardiovascular disease-related diet and lifestyle factors
Food Nutr Res, 62
DOI 10.29219/fnr.v62.1370, PubMed 29720928

Svendsen K, Telle-Hansen VH, Mørch-Reiersen LT, Garstad KW, Thyholt K, Granlund L, Henriksen HB, Gran JM, Jacobs DR, Retterstøl K (2018)
A randomized controlled trial in Norwegian pharmacies on effects of risk alert and advice in people with elevated cardiovascular risk
Prev Med Rep, 12, 79-86
DOI 10.1016/j.pmedr.2018.08.004, PubMed 30191097

Talvik A, Rebora P, Heinpalu-Kuum M, Salerno S, Miszkowska-Nagórna E, Liu X, Comotti T, Świerblewska E, Valsecchi MG, Fadl Elmula FEM, Larstorp AC, Narkiewicz K, Parati G, Laurent S, Viigimaa M, BEtter control of blood pressure in hypertensive pAtients monitored Using the hoTman® sYstem (BEAUTY) Study Investigators (2018)
Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study
Blood Press, 27 (6), 368-375
DOI 10.1080/08037051.2018.1505425, PubMed 30129785

Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Nielsen JB, Jonsson S, Halldorsson GH, Melsted P, Ivarsdottir EV, Davidsson OB, Kristjansson RP, Thorleifsson G, Helgadottir A, Gretarsdottir S, Norddahl G, Rajamani S, Torfason B, Valgardsson AS, Sverrisson JT, Tragante V, Holmen OL, Asselbergs FW, Roden DM, Darbar D, Pedersen TR, Sabatine MS et al. (2018)
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation
Commun Biol, 1, 68
DOI 10.1038/s42003-018-0068-9, PubMed 30271950

Urke EB, Søbye S, Ellingvåg A, Langslet G, Retterstøl K, Wandel M (2018)
Familial hypercholesterolemia and young patients' thoughts on own condition and treatment
Patient Educ Couns, 102 (5), 1005-1012
DOI 10.1016/j.pec.2018.12.025, PubMed 30606641

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Lancet, 392 (10155), 1311-1320
DOI 10.1016/S0140-6736(18)31652-0, PubMed 30293769

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E et al. (2018)
2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
Blood Press, 27 (6), 314-340
DOI 10.1080/08037051.2018.1527177, PubMed 30380928

Åkra S, Aksnes TA, Flaa A, Eggesbø HB, Opstad TB, Njerve IU, Seljeflot I (2018)
Interleukin-18 and the NLR family pyrin domain containing-3 inflammasome in adipose tissue are strongly associated with glucometabolic variables in a cohort of middle-aged men
Diab Vasc Dis Res, 15 (5), 458-464
DOI 10.1177/1479164118785307, PubMed 29972041